Torrent Pharmaceuticals Ltd. - Research Center
500420 TORNTPHARM Group (A) BSE data
Add to watchlist
| Results | |
| Statement |
P&L
|
| More |
Profit loss account
(Rs crore)
| Mar ' 24 | Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | |
|---|---|---|---|---|---|
| Income | |||||
| Operating income | 8,532.90 | 7,695.20 | 6,742.32 | 6,450.57 | 6,168.44 |
| Expenses | |||||
| Material consumed | 2,233.30 | 2,231.91 | 2,001.64 | 1,758.55 | 1,723.05 |
| Manufacturing expenses | 143.43 | 153.21 | 140.00 | 122.04 | 126.70 |
| Personnel expenses | 1,450.67 | 1,251.22 | 1,097.93 | 1,097.12 | 1,061.76 |
| Selling expenses | - | - | - | - | - |
| Adminstrative expenses | 1,816.20 | 1,593.70 | 1,401.99 | 1,281.13 | 1,339.94 |
| Expenses capitalised | - | - | - | - | - |
| Cost of sales | 5,643.60 | 5,230.04 | 4,641.56 | 4,258.84 | 4,251.45 |
| Operating profit | 2,889.30 | 2,465.16 | 2,100.76 | 2,191.73 | 1,916.99 |
| Other recurring income | 91.36 | 81.88 | 204.17 | 118.34 | 236.93 |
| Adjusted PBDIT | 2,980.66 | 2,547.04 | 2,304.93 | 2,310.07 | 2,153.92 |
| Financial expenses | 303.04 | 297.68 | 236.29 | 334.12 | 430.49 |
| Depreciation | 761.05 | 672.34 | 602.43 | 609.84 | 606.66 |
| Other write offs | - | - | - | - | - |
| Adjusted PBT | 1,916.57 | 1,577.02 | 1,466.21 | 1,366.11 | 1,116.77 |
| Tax charges | 559.49 | 525.63 | 474.76 | 228.26 | 178.26 |
| Adjusted PAT | 1,357.08 | 1,051.39 | 991.45 | 1,137.85 | 938.51 |
| Non recurring items | 0.44 | -7.07 | -1.55 | 7.21 | -10.76 |
| Other non cash adjustments | - | - | - | - | - |
| Reported net profit | 1,357.52 | 1,044.32 | 989.90 | 1,145.06 | 927.75 |
| Earnigs before appropriation | 4,751.73 | 4,257.24 | 3,889.81 | 3,238.36 | 2,811.80 |
| Equity dividend | 1,015.34 | 863.03 | 676.89 | 338.45 | 499.90 |
| Preference dividend | - | - | - | - | - |
| Dividend tax | - | - | - | - | 109.30 |
| Retained earnings | 3,736.39 | 3,394.21 | 3,212.92 | 2,899.91 | 2,202.60 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis